Published Paper Details:

India's 2005 shift to a product-patent regime fundamentally reshaped pharmaceutical innovation, pricing, and competition. This paper examines how patent rules particularly Sections 3(d), 84 (compulsory licensing), and 107A (Bolar exemption) affect firm behavior and public health outcomes, with a special focus on Andhra Pradesh (AP), a fast-growing pharmaceutical and med-tech hub anchored by Visakhapatnam's Jawaharlal Nehru Pharma City (JNPC), Divi's Laboratories' API facilities, and the Andhra Pradesh MedTech Zone (AMTZ). Using a mixed method doctrinal legal analysis + firm-level and cluster-level evidence we assess (i) patenting/launch patterns for APIs and formulations, (ii) spillovers on exports and employment, and (iii) access/affordability trade-offs. We interpret national precedents (e.g., Natco-Bayer compulsory licence) for their region-level implications, and map how AP's industrial policy and shared R&D/testing infrastructure mediate IPR effects. Findings aim to guide state and central decision-makers on balancing incentives for high-quality innovation with equitable access to medicines. Key recommendations include targeted R&D incentives in AP clusters, stronger Section 3(d) examination capacity, faster regulatory-IP coordination for generics under Section 107A, and cluster-wide IP facilitation cells within AMTZ/JNPC. (Key statutory anchors: Patents Act, 1970 as amended in 2005; Sections 3(d), 84, 107A.)